News

Fagron's Successful Completion of Share Buy-Back Initiative

Fagron's Successful Completion of Share Buy-Back Initiative

Fagron's Share Buy-Back Program Completion

Fagron has recently concluded an important phase in its financial strategy with the successful completion of a share buy-back program. This initiative underscores the company's commitment to enhancing shareholder value and reinforcing its capital structure.

Details of the Buy-Back Program

Between 10 November 2025 and 14 November 2025, Fagron repurchased a total of 44,000 shares. The average price for these shares was €20.7208, resulting in an overall expenditure of approximately €911,717. In total, the company has repurchased 200,000 shares under this program, with an average price of €20.6805, leading to a cumulative investment of €4,136,093.

A Focus on Strategic Growth

This strategic move to buy back shares reflects Fagron's confidence in its long-term growth and its commitment to return value to shareholders. The shares acquired will be crucial for fulfilling obligations under Fagron’s incentive schemes, aligning the interests of employees and shareholders.

Background of the Program Announcement

The announcement of the buy-back program was made on 9 October 2025, highlighting Fagron's ongoing dedication to maintaining a robust balance sheet while actively pursuing avenues to boost shareholder confidence amidst a competitive market landscape.

Future Prospects for Fagron

As Fagron continues to evolve, it remains focused on its core mission of personalized medicine. The company strives to innovate and expand its offerings to hospitals, pharmacies, and clinics globally, thereby enhancing patient care and operational efficiency.

Upcoming Financial Calendar

Fagron has laid out a comprehensive financial calendar that outlines key upcoming events. Important dates to note include:

  • Full year results 2025: 12 February 2026
  • Trading update for first quarter 2026: 9 April 2026
  • Annual General Meeting 2025: 11 May 2026
  • Half year results 2026: 30 July 2026
  • Trading update for third quarter 2026: 8 October 2026

Company Information

Fagron is a leader in pharmaceutical compounding, dedicated to providing personalized medicine across more than 35 countries. With its base in Nazareth, the company operates under the ticker symbol ‘FAGR’ on Euronext Brussels and Amsterdam.

Contact Details

For further inquiries or information, please contact:

Ignacio Artola
Global Investor Relations Leader
Ignacio.artola@fagron.com

Frequently Asked Questions

What is the purpose of the share buy-back program?

The goal of the share buy-back program is to enhance shareholder value and support the company's long-term incentive schemes.

How many shares did Fagron buy back?

Fagron repurchased a total of 200,000 shares during the buy-back program.

What was the average price of shares purchased?

The average price of shares purchased during the program was approximately €20.6805.

When was the buy-back program announced?

The buy-back program was announced on 9 October 2025.

What are Fagron's core business focuses?

Fagron primarily focuses on pharmaceutical compounding and delivering personalized medicine to improve patient care worldwide.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Etisalat Surges: Net Profit Soars 46% Amid Growth

Updated Category News Views 0

Etisalat's Stellar Performance: A Deeper Dive When a company like Etisalat drops news of a whopping 46% increase in net profit year-over-year, you sit up and pay attention. Those numbers aren’t just a flash in the pan; they're the result of some serious strategic maneuvers and ripe market conditions. Etisalat isn't resting on its laurels, and their latest financials...

Continue Reading
Backroads Invites Families: Adventures Boost Bookings by 20%

Updated Category News Views 8

Rediscovering Family Time Through Adventure When was the last time a winter vacation got you this fired up? Backroads, the trailblazer in active getaways, is bucking the trend of typical holiday madness. Families are ditching the usual gift-giving grind for something way more memorable: experiences that blend action with bonding across generations. Big Numbers, Big...

Continue Reading
Epilepsy Market's Explosive Growth Forecasted to 2036

Updated Category News Views 12

It's a wild world out there for epilepsy treatments—like a relentless bull run with everyone eyeing the prize. The latest buzz points to a fat 2036 forecast for this sector, driven by a mix of standout technologies and breakthrough therapies. You'd be a fool to blink and miss it. Rising Numbers Stir the Market The numbers, oh boy, they're climbing. In 2025, about 7...

Continue Reading
Antibiotic Overuse for Sinus Infections Costs Billions

Updated Category News Views 21

Sinus Infections: A Case of Excess Prescriptions You'd think with all the guidelines, doctors would've nailed the sinusitis treatment by now. But nope—antibiotic overuse remains alive and kicking. A fresh dig from Motive Medical Intelligence shows that more than three-quarters of primary care clinicians are quick to hand out antibiotics for acute sinusitis. So here we...

Continue Reading
Energy Fuels Secures Key Financing for Donald Project

Updated Category News Views 178

Donald Project: A Step Closer to Reality Look, when those rare earths start moving, the entire market gets a whiff of promise. Energy Fuels' Donald Rare Earth and Mineral Sands Project in Australia is gearing up for real action with a fresh funding nod. Export Finance Australia and the National Reconstruction Fund Corporation have conditionally greenlit up to A$180...

Continue Reading
Americans' Faith in Democracy Hits New Lows

Updated Category News Views 0

Polarization Beyond Politics: A National Reckoning When you catch wind of a report like this one, it's enough to make you feel like the fabric of democracy is unraveling right before our eyes. We're staring at a national identity crisis, folks, and it's got nothing to do with whether you're waving a red or blue flag. This ain't about party lines; it's about a bigger,...

Continue Reading
Pii's Odyssey Ignites Epic Cosmic Adventure

Updated Category News Views 113

A Cosmic Journey Begins Well, here's a fresh start to a galactic escapade or two! LaMont Schiers, with his brain teeming post a vivid dream, plunges headfirst into the science fiction scene. 'Pii's Odyssey: The Eternals' isn't your average bedtime read. Oh no, this is where a 14-year-old warrior kid named Pii gets yanked from his comfy home planet and tossed into a...

Continue Reading
Capacity LLC: Finalist in 2026 BeautyMatter Awards

Updated Category News Views 25

A Nod to Logistics and Beauty When beauty meets logistics, you end up with something like Capacity LLC making headlines in the 2026 BeautyMatter Awards. Now, I ain't one to usually get excited about anything involving freight and boxes, but this isn't just any nod in the 'Best Logistics Solution' category; it speaks volumes about where the beauty business is heading. Why...

Continue Reading
ALHC Faces Fraud Probe After 16% Stock Plummet

Updated Category News Views 28

Investors Eye Alignment's Tumultuous Turn One thing I don't do is sugarcoat it—stocks get hit hard sometimes, and Alignment Healthcare's recent saga has got jaws dropping across trading floors. It's only October, but Alignment's stock took a chilling nosedive on July 8, to the tune of 16.7%, leaving investors wide-eyed and demanding answers. What caused this seismic...

Continue Reading
Bladex Delivers Strong Q3 With $63M Net Profit

Updated Category News Views 63

Bladex Reports Impressive Q3 Profits Amid a sea of financial updates, Bladex's third-quarter numbers stand out like a lighthouse. They just flashed a $63.2 million net profit—up 15% from last year. That's the kind of growth that gets investors talking over their morning coffee. The magic behind these figures? Bladex managed to wrangle more revenue from net interest...

Continue Reading

Top 5 Most Recently Viewed Articles

Zenas BioPharma Class Action: Your Chance to Lead the Charge

Updated Category News Views 135

Opportunity to Lead Class Action Lawsuit for Zenas BioPharma Investors Investors of Zenas BioPharma, Inc. (NASDAQ: ZBIO) who have suffered substantial financial losses have a vital chance to become a lead plaintiff in an ongoing class action lawsuit. This opportunity stems from the registration statement connected to the company’s initial public offering (IPO)....

Continue Reading
Toyota Motor Adjusts EV Production Plans Amid Market Shifts

Updated Category News Views 173

Toyota Adjusts Its Production Strategies Toyota Motor Corporation (NYSE: TM) has recently faced a decline in its shares following the announcement of a major reduction in its electric vehicle production target for 2026. The company now aims to produce one million electric vehicles, which is a 30% decrease from its earlier forecast. This change is a response to a...

Continue Reading
Investors Urged to Explore Legal Options Against Fluence Energy

Updated Category News Views 363

Investors Encouraged to Take Action Against Fluence Energy Faruqi & Faruqi, LLP, a prominent national securities law firm, is actively investigating potential claims against Fluence Energy, Inc. (NASDAQ: FLNC). Recent market fluctuations have led to concerns that investors may have suffered significant financial losses. If you have incurred losses exceeding $75,000 in...

Continue Reading
Christopher A. DeNicola Takes Helm as CEO of Precision Spine

Updated Category News Views 215

Leadership Change at Precision Spine In a significant move, Precision Spine, Inc., a recognized leader in spinal pathology solutions, has announced the promotion of Christopher A. DeNicola to the role of President and Chief Executive Officer. This transition, which is effective immediately, places DeNicola in charge of guiding the company's strategic vision and...

Continue Reading
How Alliance Pharmaceuticals is Transforming Brand Protection

Updated Category News Views 120

Alliance Pharmaceuticals and TrueMed Forge New Partnership An innovative collaboration has emerged between Alliance Pharmaceuticals Ltd and TrueMed, aimed at tackling the ever-growing menace of counterfeit pharmaceuticals. This partnership leverages cutting-edge AI technology for efficient counterfeit detection, marking a significant shift in the operational landscape of...

Continue Reading